SmartTRAK reports on two studies presented at INS 2017 evaluating the effect of VNS paired with rehab in stroke patients with upper limb paralysis.

One of the hottest emerging applications for neuromodulation is for improving function and movement in patients paralyzed by a stroke. Stroke affects almost 800,000 people every year in the US alone and is a leading cause of long-term disability, with an annual cost to the healthcare system of ~$33 billion.

At the International Neuromodulation Society (INS) 13th Annual Congress May 26-June 3 in Edinburgh, SmartTRAK interviewed Jesse Dawson, MD, Clinical Lead, Scottish Stroke Research Network, and Teresa Kimberley, PT, PhD Associate Professor, Division of Physical Therapy at the University of Minnesota, regarding a randomized, double-blinded trial evaluating the effect of vagal nerve stimulation (VNS) during stroke rehabilitation on upper limb function after an ischemic stroke using Microtransponder’s Vivistim System...

International Neuromodulation Society (INS) President Tim Deer, MD discusses important research results as well as key trends and technologies in neuromodulation.

Timothy Deer, MD, FIPP, President of the International Neuromodulation Society (INS),  at the INS 13th Annual Congress May 26-June 3 highlighted key studies, trends and technologies in neuromodulation in an interview with SmartTRAK in Edinburgh, Scotland...

Nevro:  The One to Beat!

In an interview with BioMedGPS, Nevro CEO Rami Elghandour discussed the Company’s success, its growth strategies, and some of the challenges of being the one to beat in the spinal cord stimulation (SCS) market.

Since disrupting the market with its paresthesia-free high frequency (HF10) Senza SCS System, Nevro has set a new standard of care for SCS with unparalleled clinical evidence and success in treating chronic intractable leg and back pain.

SmartTRAK Customer Testimonial

SmartTRAK user, Scott Brown, Director Strategic New Market Development, Integra LifeSciences tells why he uses SmartTRAK to manage his business every single day.

Scott Brown Video Testimonial

It’s been less than a year since Nuvectra Medical spun-off from Greatbatch Inc. (now Integer), and in that time Nuvectra has built a sales organization and laid the organizational foundation to become a, multi-indication neurostimulation company.

In an interview with BioMedGPS, Medtronic’s Marshall Stanton, MD discussed the Company’s strategies for gaining back market share in spinal cord stimulation and ongoing efforts to find the sweet spot in treating chronic intractable pain.

An Interview with Medtronic’s Brett Wall, Sr. VP and President, Brain Therapies and Scott Hutton, VP and General Manager, Neurosurgery